206 related articles for article (PubMed ID: 22031830)
1. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Moura DS; Sultan S; Georgin-Lavialle S; Pillet N; Montestruc F; Gineste P; Barete S; Damaj G; Moussy A; Lortholary O; Hermine O
PLoS One; 2011; 6(10):e26375. PubMed ID: 22031830
[TBL] [Abstract][Full Text] [Related]
2. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Lortholary O; Chandesris MO; Bulai Livideanu C; Paul C; Guillet G; Jassem E; Niedoszytko M; Barete S; Verstovsek S; Grattan C; Damaj G; Canioni D; Fraitag S; Lhermitte L; Georgin Lavialle S; Frenzel L; Afrin LB; Hanssens K; Agopian J; Gaillard R; Kinet JP; Auclair C; Mansfield C; Moussy A; Dubreuil P; Hermine O
Lancet; 2017 Feb; 389(10069):612-620. PubMed ID: 28069279
[TBL] [Abstract][Full Text] [Related]
3. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Paul C; Sans B; Suarez F; Casassus P; Barete S; Lanternier F; Grandpeix-Guyodo C; Dubreuil P; Palmérini F; Mansfield CD; Gineste P; Moussy A; Hermine O; Lortholary O
Am J Hematol; 2010 Dec; 85(12):921-5. PubMed ID: 21108325
[TBL] [Abstract][Full Text] [Related]
4. Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.
Moura DS; Sultan S; Georgin-Lavialle S; Barete S; Lortholary O; Gaillard R; Hermine O
PLoS One; 2012; 7(6):e39468. PubMed ID: 22745762
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychological features of adult mastocytosis.
Moura DS; Georgin-Lavialle S; Gaillard R; Hermine O
Immunol Allergy Clin North Am; 2014 May; 34(2):407-22. PubMed ID: 24745683
[TBL] [Abstract][Full Text] [Related]
6. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of masitinib for treating systemic mastocytosis.
Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
[No Abstract] [Full Text] [Related]
8. Leukocyte telomere length in mastocytosis: correlations with depression and perceived stress.
Georgin-Lavialle S; Moura DS; Bruneau J; Chauvet-Gélinier JC; Damaj G; Soucie E; Barete S; Gacon AL; Grandpeix-Guyodo C; Suarez F; Launay JM; Durieu I; Esparcieux A; Guichard I; Sparsa A; Nicolini F; Gennes Cd; Trojak B; Haffen E; Vandel P; Lortholary O; Dubreuil P; Bonin B; Sultan S; Teyssier JR; Hermine O
Brain Behav Immun; 2014 Jan; 35():51-7. PubMed ID: 23917070
[TBL] [Abstract][Full Text] [Related]
9. Mastocytosis in adulthood and neuropsychiatric disorders.
Georgin-Lavialle S; Gaillard R; Moura D; Hermine O
Transl Res; 2016 Aug; 174():77-85.e1. PubMed ID: 27063957
[TBL] [Abstract][Full Text] [Related]
10. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions.
Jennings S; Russell N; Jennings B; Slee V; Sterling L; Castells M; Valent P; Akin C
J Allergy Clin Immunol Pract; 2014; 2(1):70-6. PubMed ID: 24565772
[TBL] [Abstract][Full Text] [Related]
11. Masitinib for the treatment of mild to moderate Alzheimer's disease.
Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
[TBL] [Abstract][Full Text] [Related]
12. Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA; Ogilvie G; Rusk T; Devauchelle P; Leblanc A; Legendre A; Powers B; Leventhal PS; Kinet JP; Palmerini F; Dubreuil P; Moussy A; Hermine O
J Vet Intern Med; 2008; 22(6):1301-9. PubMed ID: 18823406
[TBL] [Abstract][Full Text] [Related]
13. Case-control cohort study of patients' perceptions of disability in mastocytosis.
Hermine O; Lortholary O; Leventhal PS; Catteau A; Soppelsa F; Baude C; Cohen-Akenine A; Palmérini F; Hanssens K; Yang Y; Sobol H; Fraytag S; Ghez D; Suarez F; Barete S; Casassus P; Sans B; Arock M; Kinet JP; Dubreuil P; Moussy A
PLoS One; 2008 May; 3(5):e2266. PubMed ID: 18509466
[TBL] [Abstract][Full Text] [Related]
14. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P; Letard S; Ciufolini M; Gros L; Humbert M; Castéran N; Borge L; Hajem B; Lermet A; Sippl W; Voisset E; Arock M; Auclair C; Leventhal PS; Mansfield CD; Moussy A; Hermine O
PLoS One; 2009 Sep; 4(9):e7258. PubMed ID: 19789626
[TBL] [Abstract][Full Text] [Related]
15. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
16. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
[TBL] [Abstract][Full Text] [Related]
17. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis.
Barete S; Lortholary O; Damaj G; Hirsch I; Chandesris MO; Elie C; Hamidou M; Durieu I; Suarez F; Grosbois B; Limal N; Gyan E; Larroche C; Guillet G; Kahn JE; Casassus P; Amazzough K; Coignard-Biehler H; Georgin-Lavialle S; Lhermitte L; Fraitag S; Canioni D; Dubreuil P; Hermine O
Blood; 2015 Aug; 126(8):1009-16; quiz 1050. PubMed ID: 26002962
[TBL] [Abstract][Full Text] [Related]
19. Psychological functioning and quality of life in patients with mastocytosis: A cross-sectional study.
Vermeiren MR; Kranenburg LW; van Daele PLA; Gerth van Wijk R; Hermans MAW
Ann Allergy Asthma Immunol; 2020 Apr; 124(4):373-378.e2. PubMed ID: 31923542
[TBL] [Abstract][Full Text] [Related]
20. Response of patients with indolent systemic mastocytosis to tamoxifen citrate.
Butterfield JH; Chen D
Leuk Res; 2016 Jan; 40():10-6. PubMed ID: 26612479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
